Sacubitril/valsartan improves all-cause mortality in heart failure patients with reduced ejection fraction and chronic kidney disease

被引:0
作者
Wei-Chieh Lee
Ting-Wei Liao
Tien-Yu Chen
Hsiu-Yu Fang
Yen-Nan Fang
Huang-Chung Chen
Yu-Sheng Lin
Shang-Hung Chang
Mien-Cheng Chen
机构
[1] National Cheng Kung University,Institute of Clinical Medicine, College of Medicine
[2] Chi Mei Medical Center,Division of Cardiology, Department of Internal Medicine
[3] Chang Gung University College of Medicine,Division of Cardiology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital
[4] National Sun Yat-sen University,School of Medicine, College of Medicine
[5] Chang-Gung University and Hospital,Center for Big Data Analytics and Statistics
[6] Chang Gung Memorial Hospital,Division of Cardiology
来源
Cardiovascular Drugs and Therapy | 2024年 / 38卷
关键词
Sacubitril/valsartan; Heart failure; Renal protection; Chronic kidney disease; All-cause mortality;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:505 / 515
页数:10
相关论文
共 57 条
[1]  
Guo Y(2013)Heart failure in East Asia Curr Cardiol Rev 9 112-122
[2]  
Lip GY(1987)Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS) N Engl J Med 316 1429-1435
[3]  
Banerjee A(1991)Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure N Engl J Med 325 293-302
[4]  
Yusuf S(2001)Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure N Engl J Med 345 1667-1675
[5]  
Pitt B(2022)2022 AHA/ACC/HFSA Guideline for the management of heart failure: executive summary: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines Circulation 145 e876-ee94
[6]  
Davis CE(2021)2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure Eur Heart J 42 3599-3726
[7]  
Hood WB(2014)PARADIGM-HF Investigators and Committees. Angiotensin-neprilysin inhibition versus enalapril in heart failure N Engl J Med 371 993-1004
[8]  
Cohn JN(2019)EVALUATE-HF Investigators. Effect of sacubitril-valsartan vs enalapril on aortic stiffness in patients with heart failure and reduced ejection fraction: a randomized clinical trial JAMA 322 1077-1084
[9]  
Cohn JN(2022)2022 AHA/ACC/HFSA Guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines Circulation 145 e895-e1032
[10]  
Tognoni G(2020)The role of the kidney in acute and chronic heart failure Heart Fail Rev 25 107-118